Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 69
- 试验地点
- 12
- 主要终点
- Change from Baseline Prostate-Specific Antigen (PSA) Score at 8 weeks [Male Subjects]
研究概览
简要总结
The goal of this observational study is to provide exploratory research into the in vivo physiological and psychological effects, if any, of cannabigerol (CBG) in healthy human adults age 21 or over.
The main questions it aims to answer are:
- What effect, if any, does daily oral consumption of 50mg of full spectrum CBG have on the mental, physical, and emotional wellbeing of healthy individuals, as measured by self-report Medical Symptom Questionnaire and 36-Item Short Form Health Survey scores?
- Is CBG effective at reducing inflammation in the body, as measured by HSCRP, ESR, and PSA inflammatory markers?
- Do age, gender, weight, or state of body inflammation have an effect on the perceived efficacy of CBG?
- What adverse effects, if any, are associated with CBG use?
Over the course of the 12-week study, participants will:
- Take baseline MSQ and SF-36 surveys, as well as a clinical visit with blood draws for HSCRP, ESR, and PSA testing
- Consume one (1) 50mg capsule of full spectrum CBG daily by mouth with food for 8 weeks, followed by a 4-week washout period
- Complete biweekly SF-36 surveys as well as MSQ surveys every 4 weeks
- Attend a clinical visit every 4 weeks for clinical observation and blood draws for HSCRP, ESR, and PSA (male subjects)
详细描述
BACKGROUND AND CONTEXT
The Cannabis plant has gained significant, and increasing, interest in the medical community due to the therapeutic potential of substances such as Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD). However, there are hundreds of different phytocannabinoids, terpenes, and flavonoids present in Cannabis plants, generating complex interactions in the human body. Cannabigerol (CBG) is one phytocannabinoid that has recently garnered a groundswell of media and commercial interest, although scientific literature on CBG is severely lacking compared with published research on Δ9-THC and CBD. Current studies suggest that CBG appears to have characteristics for affinity and activity somewhere between CBD and Δ9-THC, with additional unique interactions with 5-hydroxytryptamine (5-HT1A) receptors and α-2 adrenoceptors. Based on published research, there may be therapeutic potential for CBG in the treatment of neuroinflammatory disorders, inflammatory bowel disease, bacterial infections (such as MRSA), prostate cancer, and dental plaque. Many of these studies, however, indicate a vital need for additional research on the pharmacological effects of human CBG consumption, especially given the increase in its unregulated commercial use. This study will focus on the clinical application of CBG for healthy adults, current knowledge of its possible therapeutic utility, and its potential toxicological hazards.
PROBLEM STATEMENT
Cannabigerol is currently available for purchase in a variety of products and, as with cannabidiol (CBD) before it, many claims are being made about its benefits. Unlike CBD, however, little in-depth research has been performed on this intriguing phytocannabinoid, and much of what is known warrants further investigation to identify potential areas of therapeutic uses and hazards.
RESEARCH QUESTIONS
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •In good overall health (as determined by the supervising healthcare provider recommendation as well as no indications of Moderate or Severe conditions on the study measurement tools)
- •21 years old or over
- •No conditions determined at risk for adverse reactions to the product ingredients
- •Research participants with the potential to become pregnant are eligible to be included in the study as long as they are sexually abstinent or using a contraceptive method considered effective.
排除标准
- •Under the age of 21
- •Is pregnant or breastfeeding
- •Initiated or changed use of medication or therapies within 2 weeks prior to the start of the study
- •Has a history of hepatic compromise (with transaminases of two times the upper limit of normal) or cirrhosis
- •Is already using recreational marijuana, medical marijuana or other cannabinoid formulations (including CBD)
- •Has a history of substance or alcohol abuse
- •Is using High Dose or Extended-Release Narcotics
结局指标
主要结局
Change from Baseline Prostate-Specific Antigen (PSA) Score at 8 weeks [Male Subjects]
时间窗: 8 weeks
Blood concentration, measured in ng/mL
Change from Baseline Medical Symptom Questionnaire (MSQ) Score at 8 weeks
时间窗: 8 weeks
Change from baseline scores as measured by the Medical Symptom Questionnaire after 8 weeks. A total score of 20 or less is not clinically significant, 20 to 49 indicates mild toxicity, 50 to 99 indicates moderate toxicity, and 100 and above indicates severe toxicity.
Change from Baseline RAND 36-Item Short Form Survey (SF-36) Scores at 8 weeks
时间窗: 8 weeks
Change from baseline scores as measured by the RAND 36-Item Short Form Survey after 8 weeks. Scores range from 0-100 for the 8 scales included (physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, and general health), with higher scores representing a more favorable health state.
Change from Baseline High-Sensitivity C-reactive Protein (hsCRP) at 8 weeks
时间窗: 8 weeks
Blood concentration, measured in mg/L
Change from Baseline Erythrocyte Sedimentation Rate (ESR) at 8 weeks
时间窗: 8 weeks
Blood concentration, measured in mm/hour
次要结局
未报告次要终点